Latest Insider Transactions at Day One Biopharmaceuticals, Inc. (DAWN)
This section provides a real-time view of insider transactions for Day One Biopharmaceuticals, Inc. (DAWN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Day One Biopharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Day One Biopharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 15
2022
|
Samuel C. Blackman HEAD OF R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
1,187
+0.09%
|
-
|
Nov 15
2022
|
Charles N York Ii COO, CFO AND SECRETARY |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+0.46%
|
-
|
Nov 02
2022
|
Papanek Julie Grant Director |
SELL
Open market or private sale
|
Indirect |
5,000
-1.18%
|
$100,000
$20.01 P/Share
|
Nov 01
2022
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
12,500
-1.02%
|
$250,000
$20.03 P/Share
|
Nov 01
2022
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
10,000
-0.78%
|
$200,000
$20.0 P/Share
|
Nov 01
2022
|
Papanek Julie Grant Director |
SELL
Open market or private sale
|
Indirect |
5,000
-1.16%
|
$100,000
$20.04 P/Share
|
Nov 01
2022
|
Charles N York Ii COO, CFO AND SECRETARY |
SELL
Open market or private sale
|
Direct |
10,000
-3.29%
|
$200,000
$20.03 P/Share
|
Oct 04
2022
|
Papanek Julie Grant Director |
SELL
Open market or private sale
|
Indirect |
5,000
-1.15%
|
$100,000
$20.0 P/Share
|
Oct 03
2022
|
Charles N York Ii COO, CFO AND SECRETARY |
SELL
Open market or private sale
|
Direct |
10,000
-3.18%
|
$200,000
$20.05 P/Share
|
Oct 03
2022
|
Papanek Julie Grant Director |
SELL
Open market or private sale
|
Indirect |
5,000
-1.14%
|
$100,000
$20.06 P/Share
|
Oct 03
2022
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
10,000
-0.78%
|
$190,000
$19.99 P/Share
|
Oct 03
2022
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
12,500
-1.01%
|
$250,000
$20.05 P/Share
|
Sep 21
2022
|
Papanek Julie Grant Director |
SELL
Other acquisition or disposition
|
Indirect |
1,500,000
-17.72%
|
-
|
Sep 21
2022
|
Papanek Julie Grant Director |
SELL
Open market or private sale
|
Indirect |
613,603
-3.38%
|
$11,044,854
$18.92 P/Share
|
Sep 21
2022
|
Canaan Xi L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
1,500,000
-17.72%
|
-
|
Sep 21
2022
|
Canaan Xi L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
613,603
-3.38%
|
$11,044,854
$18.92 P/Share
|
Sep 20
2022
|
Papanek Julie Grant Director |
SELL
Open market or private sale
|
Indirect |
148,670
-0.81%
|
$2,824,730
$19.8 P/Share
|
Sep 20
2022
|
Canaan Xi L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
148,670
-0.81%
|
$2,824,730
$19.8 P/Share
|
Sep 19
2022
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
600,854
-8.33%
|
-
|
Sep 19
2022
|
Papanek Julie Grant Director |
SELL
Open market or private sale
|
Indirect |
76,725
-0.82%
|
$1,534,500
$20.57 P/Share
|
Sep 19
2022
|
Canaan Xi L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
76,725
-0.82%
|
$1,534,500
$20.57 P/Share
|
Sep 16
2022
|
Papanek Julie Grant Director |
SELL
Open market or private sale
|
Indirect |
115,307
-0.61%
|
$2,421,447
$21.79 P/Share
|
Sep 16
2022
|
Canaan Xi L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
115,307
-0.61%
|
$2,421,447
$21.79 P/Share
|
Sep 15
2022
|
Canaan Xi L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
51,281
-0.27%
|
$1,179,463
$23.26 P/Share
|
Sep 15
2022
|
Papanek Julie Grant Director |
SELL
Open market or private sale
|
Indirect |
51,281
-0.27%
|
$1,179,463
$23.26 P/Share
|
Sep 14
2022
|
Canaan Xi L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
106,111
-0.55%
|
$2,440,553
$23.99 P/Share
|
Sep 14
2022
|
Papanek Julie Grant Director |
SELL
Open market or private sale
|
Indirect |
106,111
-0.55%
|
$2,440,553
$23.99 P/Share
|
Sep 13
2022
|
Canaan Xi L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
87,647
-0.45%
|
$2,103,528
$24.7 P/Share
|
Sep 13
2022
|
Papanek Julie Grant Director |
SELL
Open market or private sale
|
Indirect |
87,647
-0.45%
|
$2,103,528
$24.7 P/Share
|
Sep 02
2022
|
Papanek Julie Grant Director |
SELL
Open market or private sale
|
Indirect |
5,000
-1.13%
|
$115,000
$23.82 P/Share
|
Sep 01
2022
|
Charles N York Ii COO, CFO AND SECRETARY |
SELL
Open market or private sale
|
Direct |
10,000
-1.55%
|
$230,000
$23.48 P/Share
|
Sep 01
2022
|
Papanek Julie Grant Director |
SELL
Open market or private sale
|
Indirect |
5,000
-0.56%
|
$115,000
$23.5 P/Share
|
Sep 01
2022
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
10,000
-0.39%
|
$230,000
$23.47 P/Share
|
Sep 01
2022
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
25,000
-0.5%
|
$575,000
$23.47 P/Share
|
Aug 16
2022
|
Charles N York Ii COO, CFO AND SECRETARY |
SELL
Open market or private sale
|
Direct |
1,089
-0.33%
|
$26,136
$24.31 P/Share
|
Aug 16
2022
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
941
-0.07%
|
$22,584
$24.31 P/Share
|
Aug 16
2022
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
4,003
-0.32%
|
$96,072
$24.31 P/Share
|
Aug 15
2022
|
Charles N York Ii COO, CFO AND SECRETARY |
BUY
Exercise of conversion of derivative security
|
Direct |
4,125
+1.25%
|
-
|
Aug 15
2022
|
Samuel C. Blackman HEAD OF R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
3,561
+0.27%
|
-
|
Aug 15
2022
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,686
+0.84%
|
-
|
Aug 05
2022
|
Papanek Julie Grant Director |
SELL
Open market or private sale
|
Indirect |
5,000
-1.1%
|
$100,000
$20.0 P/Share
|
Aug 04
2022
|
Papanek Julie Grant Director |
SELL
Open market or private sale
|
Indirect |
5,000
-1.09%
|
$100,000
$20.0 P/Share
|
Aug 04
2022
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
12,500
-0.99%
|
$250,000
$20.0 P/Share
|
Aug 04
2022
|
Charles N York Ii COO, CFO AND SECRETARY |
SELL
Open market or private sale
|
Direct |
10,000
-3.02%
|
$200,000
$20.05 P/Share
|
Aug 01
2022
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
10,000
-0.77%
|
$160,000
$16.88 P/Share
|
Jul 18
2022
|
Charles N York Ii COO, CFO AND SECRETARY |
SELL
Open market or private sale
|
Direct |
2,500
-0.75%
|
$50,000
$20.0 P/Share
|
Jul 18
2022
|
Papanek Julie Grant Director |
SELL
Open market or private sale
|
Indirect |
2,600
-0.56%
|
$52,000
$20.0 P/Share
|
Jul 18
2022
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
2,600
-0.21%
|
$52,000
$20.0 P/Share
|
Jul 08
2022
|
Papanek Julie Grant Director |
SELL
Open market or private sale
|
Indirect |
1,242
-0.27%
|
$24,840
$20.0 P/Share
|
Jul 08
2022
|
Charles N York Ii COO, CFO AND SECRETARY |
SELL
Open market or private sale
|
Direct |
1,416
-0.42%
|
$28,320
$20.0 P/Share
|